Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis
- PMID:31254879
- DOI: 10.1016/j.psychres.2019.06.020
Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis
Abstract
There is a pressing need for better pharmacological treatment strategies for psychiatric disorders as current treatment often results in partial symptom remission and unwanted side effects. A point of entry may be the glutamatergic system since glutamatergic dysregulation contributes to multiple psychiatric disorders. We evaluated the evidence from randomized controlled trials (RCTs) regarding the use of the glutamatergic drug riluzole in mental illnesses; and conducted preliminary meta-analyses of its effectiveness in treating obsessive-compulsive disorder (OCD) and depression. A systematic search was performed using PubMed (Medline), Embase, Cochrane Database of Systematic Reviews and PsycINFO. Meta-analyses were performed using Comprehensive Meta-Analysis software. Twenty-three RCTs were included for qualitative analysis and showed positive effects of adjunctive/monotherapy riluzole in patients with OCD, depression, autism, substance abuse and schizophrenia. Seven studies were also used for quantitative analysis, which revealed positive but non-significant effects on OCD and depression. Riluzole was generally well tolerated with few serious adverse events. The studies included in this systematic review were highly heterogeneous and the number of studies was limited per diagnostic condition. Moreover, few studies have examined riluzole as a single treatment. We suggest carrying out further work to provide definitive evidence for the benefit of riluzole in psychiatric illness.
Keywords: Meta-analysis; Psychiatric disorder; Riluzole; Systematic review.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
- Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.Yao R, Wang H, Yuan M, Wang G, Wu C.Yao R, et al.Psychiatry Res. 2020 Feb;284:112750. doi: 10.1016/j.psychres.2020.112750. Epub 2020 Jan 7.Psychiatry Res. 2020.PMID:31958711
- Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders.Slotema CW, Blom JD, Hoek HW, Sommer IE.Slotema CW, et al.J Clin Psychiatry. 2010 Jul;71(7):873-84. doi: 10.4088/JCP.08m04872gre. Epub 2010 Mar 9.J Clin Psychiatry. 2010.PMID:20361902
- Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review.Kawashima Y, Yamada M, Furuie H, Kuniishi H, Akagi K, Kawashima T, Noda T, Yamada M.Kawashima Y, et al.Neuropsychopharmacol Rep. 2023 Sep;43(3):320-327. doi: 10.1002/npr2.12364. Epub 2023 Jul 18.Neuropsychopharmacol Rep. 2023.PMID:37463744Free PMC article.Review.
- Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH.Coric V, et al.Biol Psychiatry. 2005 Sep 1;58(5):424-8. doi: 10.1016/j.biopsych.2005.04.043.Biol Psychiatry. 2005.PMID:15993857Clinical Trial.
- Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder.Grant P, Song JY, Swedo SE.Grant P, et al.J Child Adolesc Psychopharmacol. 2010 Aug;20(4):309-15. doi: 10.1089/cap.2010.0009.J Child Adolesc Psychopharmacol. 2010.PMID:20807069Free PMC article.Review.
Cited by
- Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission.Montanari M, Martella G, Bonsi P, Meringolo M.Montanari M, et al.Int J Mol Sci. 2022 Mar 31;23(7):3861. doi: 10.3390/ijms23073861.Int J Mol Sci. 2022.PMID:35409220Free PMC article.Review.
- Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.Vingerhoets C, Tse DH, van Oudenaren M, Hernaus D, van Duin E, Zinkstok J, Ramaekers JG, Jansen JF, McAlonan G, van Amelsvoort T.Vingerhoets C, et al.J Psychopharmacol. 2020 Aug;34(8):856-863. doi: 10.1177/0269881120922977. Epub 2020 May 25.J Psychopharmacol. 2020.PMID:32448020Free PMC article.Clinical Trial.
- Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.Spangler PT, West JC, Dempsey CL, Possemato K, Bartolanzo D, Aliaga P, Zarate C, Vythilingam M, Benedek DM.Spangler PT, et al.J Clin Psychiatry. 2020 Oct 27;81(6):20m13233. doi: 10.4088/JCP.20m13233.J Clin Psychiatry. 2020.PMID:33113596Free PMC article.Clinical Trial.
- Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology.Nasir M, Trujillo D, Levine J, Dwyer JB, Rupp ZW, Bloch MH.Nasir M, et al.Front Psychiatry. 2020 Nov 19;11:548505. doi: 10.3389/fpsyt.2020.548505. eCollection 2020.Front Psychiatry. 2020.PMID:33329087Free PMC article.Review.
- Novel drug developmental strategies for treatment-resistant depression.Borbély É, Simon M, Fuchs E, Wiborg O, Czéh B, Helyes Z.Borbély É, et al.Br J Pharmacol. 2022 Mar;179(6):1146-1186. doi: 10.1111/bph.15753. Epub 2022 Jan 26.Br J Pharmacol. 2022.PMID:34822719Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical